ADCYAP1 and type 2 diabetes mellitus: Based on these observations, however, it is plausible that PACAP could also be protective in neuropathies observed in type II diabetes, as the main mechanism of neuropathic induction is not directly related to the model itself but more to the increased glucose levels.